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In this thesis we aimed to study the contribution of proteoglycans (PG) in innate immune-
derived renal injury in transplantation and native kidney diseases. To this end we designed
studies to look at the different aspects of innate immunity and their interaction with PGs
in proteinuria, renal ischemia/reperfusion (I/R) and transplantation. As discussed in the
introduction (Chapter 1) of this thesis, innate immunity as the first line of defense, is in-
volved in the pathogenesis of renal injury in proteinuria (1, 2), I/R (3) and transplantation
(4).The innate immune system consists of cellular and humoral components. Leukocytes
build the cellular arm, while complement system and cytokines form the humoral arm
of innate immune system. Involvement of inflammation and complement system in pro-
teinuria, I/R and transplantation has already been established (1, 3–7). The alternative
pathway (AP) of the complement system is spontaneously and constantly activated on
biological surfaces and may lead to cell lysis, opsonization and amplification of inflamma-
tory signals. The AP plays an important role in a number of renal diseases (8). Mutations
in components of the AP can play a role in the pathophysiology of renal damage by ham-
pering AP regulation. In proteinuric renal disease, proteinuria can activate the AP by two
different mechanisms. First, the serum proteins filtered in urine were shown to stimulate
renal tubular cells to produce complement factors and second, the complement factors
present in the ultrafiltrate can activate the pathway on tubular cells (1). In renal I/R,
complement activation occurs mostly via the AP and the Mannose-Lectin binding pathway
(9, 10). In renal transplantation, the AP is activated in both acute and chronic rejection
(11, 12). Since AP of complement plays an important role in tubule-interstitial injury in
all three abovementioned settings, namely proteinuria, I/R and transplantation, in this
thesis we mainly focused on the contribution of PGs in AP-mediated tubulo-interstitial
injury.
Properdin is the only positive regulator of the AP and it can initiate the AP by
binding to cell surfaces (13). However its ligand on cells was not yet identified. Factor
H is the main inhibitor of the AP both on the cell surface and the fluid phase. Factor
H is known to interact with PGs on the cell surface (14). Moreover, both properdin and
factor H are recognition molecules of AP which can differentiate between host cells and
pathogens (14). Considering these facts, we were interested to investigate properdin and
PGs as well as factor H and PGs interaction in proteinuric rat models. In Chapter 2
we identified tubular heparan sulfate proteoglycans (HSPG) as the ligands for properdin
which is present in the ultrafiltrate. Furthermore, we demonstrated that interaction of
properdin with tubular HSPG leads to AP activation on renal tubular cells. Additionally,
we assessed the molecular binding properties of glycosaminoglycans (GAG) for binding to
properdin. In Chapter 3 we confirmed previous studies showing factor H-PG interaction
on tubular cells. Besides we showed the ability of factor H to inhibit AP activation on
tubular cells via interaction with tubular HSPGs. Based on our results, we concluded
that during proteinuria both factor H and properdin are present in the ultrafiltrate, and
both can interact with tubular HSPGs (Fig. 7.1).
Next, we compared the binding properties of GAGs for both properdin and factor
H. A series of competition ELISA assays were designed to determine whether or not
properdin and factor H compete for the same motif on HS or they recognize different
binding sites. This is important from the therapeutical point of view, to design a drug
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Figure 7.1: Schematic picture summarizing the findings in Chapter 2 and 3. It is
proposed that factor H (fH) and properdin (P), present in ultrafiltrate during proteinuria, bind
to tubular heparan sulfate proteoglycans (HSPGs). Binding of properdin to tubular HSPGs leads
to alternative pathway activation on tubular cells while factor H interaction with tubular HSPGs
prevents the activation of alternative pathway.
which targets the properdin interaction with PGs, however does not influence the factor
H function. The ideal drug to suppress the activation of AP during proteinuria, will
inhibit properdin from initiating the AP while it does not interfere with factor H-tubular
HS interaction. In Chapter 3 we demonstrated that properdin and factor H did not
compete with each other to interact with HSPGs. Thus, they bind to different motifs on
tubular HSPGs (as illustrated in Fig. 7.2). It seemed that properdin interacts easier with
HSPGs while factor H needs higher sulfation in order to bind to HSPGs. We thus showed
that these interactions could be manipulated by certain low anticoagulant heparinoids
in favor of AP inhibition. Due to a high degree of sulfation, unfractionated heparin
inhibited both properdin and factor H interaction with HSPGs. Besides, heparin, as
mentioned before, has anticoagulant activity which is not desirable in physiologic context.
Our results demonstrated the ability of some low anticoagulant heparinoid preparations
in selective blockade of properdin-HSPG interaction while factor H-HSPG interaction
remains intact in presence of these heparinoids. These data provide a basis for targeted,
specific heparinoid interventions in proteinuric renal diseases.
It is known that the AP is activated after renal transplantation, and it has also been
shown that AP plays a role in both acute and chronic rejection (6, 12). As the above
data support a role for therapeutic effects of specific heparinoids, we hypothesized that
heparionoid intervention might provide renoprotection in chronic transplant dysfunction.
To test this hypothesis, in Chapter 4 we used a rodent transplantation model to intervene
with heparin and two different non-anticoagulant heparinoids with different levels of sul-
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Figure 7.2: Picture illustrating the binding motifs on the glycosaminoglycan (GAG)
chains of heparan sulfate proteoglycans. Factor H (fH) and properdin (P) both bind to hep-
aran sulfate proteoglycans. However they interact with different motifs on HSPG. Modifications
(e.g. sulfation groups) on GAG chains define the binding. Properdin is able to bind to a lower
sulfated GAG chain, while factor H needs a higher degree of sulfation for binding. Therefore, it
indicates the importance of tubular HSPG pattern in regulation of AP in proteinuria.
fation. Over time we followed loss of renal function by measuring serum urea, creatinine
and the development of proteinuria. We also quantified leukocyte influx and expres-
sion of complement factors in the transplanted kidneys. Renal function loss was similar
for heparin(oid) treated and vehicle treated animals. However, the R-O heparin treated
group showed a tendency towards reduction of proteinuria. We found a reduced number
of CD45+ inflammatory cells in the tubulo-interstitium of R-O heparin treated animals
but simultaneously the same group showed significantly increased properdin expression,
mainly in the glomeruli. Factor H expression was similar in heparin(oid) treated and ve-
hicle treated animals. However, we could not show any difference in activation of the AP
(measured by C3 and MAC deposition in renal tissue). Since properdin freshly secreted
from neutrophils is monomeric and does not bind to HSPG (unpublished data, Zaferani
et al), we suggest that the higher expression of properdin in R-O heparin treated group is
not properly functional to activate the AP. Nevertheless, it would be interesting to look
for neutrophil influx in these animals in tubulo-interstitium and glomeruli.
So, the results of intervention were modest, and mainly limited to a lower influx of
CD45 positive cells. These data support the concept that heparinoids can modify processes
of renal damage, but also, that the effect is not straightforward. Our data also support
the concept that specificity of heparinoids is important for the possible therapeutic effect.
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Hence, heparinoids should be chosen carefully to target the desired interaction. Moreover,
pharmacokinetic considerations, such as dose-response, deserve proper attention. It has
been shown that exogenous heparinoids can interfere with the growth factor signaling
and inflammation (15–17). As we discussed earlier in this thesis, PGs are involved in
several levels of innate inflammatory response. Leukocyte rolling, adhesion, activation,
extravasation and migration are partly mediated by PGs. In addition, binding of PGs
to various chemokines, cytokines and complement factors has an important role in innate
immune system activation. Therefore, heparinoids can potentially be used to target any of
these interactions. Further research is needed to characterize the binding properties of PGs
for selectins, integrins, chemokines, cytokines and complement factors in order to enable
us to target the desired interaction more efficiently. In addition to (low molecular weight)
heparins, other heparinoids with low anticoagulant activity such as K5 preparations (18),
other natural GAGs (e.g. some heparan sulfates or chondroitin sulfates or GAGs from
algae or invertebrate animals), or synthetic HS mimetics could be considered for potential
therapeutic use.
Basement membrane PGs have been shown to be involved in leukocyte recruitment to
the injured tissue (19). Two of the basement membrane PGs are collagen XV and col-
lagen XVIII. These two collagens/PGs are best known for their anti-angiogenic activity
via their C-terminal domains. Chapter 5 focuses on cellular components of innate immu-
nity and on the role of basement membrane PGs in leukocyte recruitment to renal tissue
upon I/R. We used knockout mice for basement membrane proteoglycans, namely colla-
gen XV, collagen XVIII and their compound mutant to evaluate the influx of neutrophils
and macrophages into renal tissue after I/R injury. Indeed, the compound mutant mice
lacking both basement membrane HSPGs (collagen XV and XVIII) showed a decrease in
number of neutrophils and macrophages to kidney comparing to wildtype mice. Moreover,
these double mutant mice showed less tubular damage and reduced tubular cell activa-
tion. Serum urea levels showed a reduction in double mutant mice which is indicative of
a better renal function after I/R. Less tubular damage and a better renal function might
be due to a milder inflammatory response after I/R in collagen XV and XVIII deficient
mice. However, the exact mechanism of the collagen XV and XVIII involvement in in-
flammatory cell influx is not well understood. Taken together our data with the results
from previous studies, three possible mechanisms can be suggested. First, broadened
(vascular) basement membranes (20) in the KO mice can be a durable barrier for leuko-
cyte influx. Second, collagen XV and XVIII like other basement membrane PGs might
interact with leukocyte adhesion molecules and facilitate leukocyte migration (19, 21, 22).
Third, basement membrane collagen XV and XVIII can play a role in chemokine gradient
formation guiding leukocyte migration. We concluded that basement membrane HSPGs
play an important role in leukocyte recruitment and renal tissue damage after I/R. Our
results thus showed a new role for collagen XV and collagen XVIII as HSPGs besides their
anti-angiogenic function. HSPGs have been shown to interact with complement factors
(Chapter 1). Moreover, complement system has an established role in pathogenesis of
I/R injury. Thus, it would be interesting to check for the complement activation in this
model as well. Future research can unravel a potential role of basement membrane col-
lagen/HSPGs in development of complement derived I/R injury. Innate immune system
activation is notable in renal fibrosis. Involvement of Toll-like receptors, macrophages and
dendritic cells in renal fibrosis has been shown (23, 24). Depletion of macrophages has been
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shown to be beneficial and ameliorates renal fibrosis after various injuries, while adoptive
transfer of macrophages aggravates the fibrotic lesions, demonstrating their profibrotic
roles in renal fibrogenesis (25). As we showed in this chapter, PGs play an important role
in leukocyte influx and activation after injury in kidney. Thus, it would be interesting to
dissect this area more, since it can bring a new approach to target progression of renal
fibrosis.
In Chapter 6, we hypothesized that factor H polymorphisms can influence the graft
outcome after renal transplantation. In a large transplant cohort database, we checked
for the association of both donor and recipients factor H tagSNPs with end stage renal
disease, graft loss and acute rejection in renal transplant recipients. Our results confirmed
the involvement of donor factor H gene variants in acute rejection after transplantation.
The associations were found in donor SNPs and not in recipients SNPs, which is suggestive
of the importance of intra-renal production of factor H. Moreover, we showed two of the
factor H SNPs to be a risk factor for end stage renal disease in a case-control analysis. All
together the results of this chapter indicate the involvement of AP in pathogenesis of both
end stage renal disease and acute rejection. However, we must mention that these data.
In a single transplant cohort, still require independent confirmation in a different cohort
– which would be a transplant cohort for confirmation of association with acute rejection,
and an ESRD cohort for the association with ESRD. Other studies have been reported no
association between the mannose-lectin binding proteins variants and renal graft outcome
after transplantation (26). Moreover, no difference was found in genetic variants of C3 and
renal transplantation outcome (27). Taken together, these results suggest AP involvement
rather than mannose-lectin pathway or classical pathway in acute renal graft rejection.
However, this issue needs further investigation.
7.2 Conclusions and Future perspective
In this thesis, we investigated some mechanisms of innate immune system involvement in
the pathogenesis of renal damage. We proposed a novel mechanism for proteinuria-derived
tubular injury via PGs interaction with complement factors. It would be interesting to
expand this research line to other complement factors specially the AP components and
terminal complement components in proteinuria. Although our results showed a defined
role for tubular HSPG in proteinuria derived renal injury, in vivo studies would be essential
to confirm the clinical use of heparinoids in reduction of tubule-interstitial inflammation
secondary to proteinuria. Rodent models of chronic proteinuria like adriamycin induced
nephropathy might be a good animal model to be treated with heparinoids. However, the
binding properties of the heparinoids for various complement factors and inhibition of the
various complement pathways should be checked in vitro beforehand.
We also showed a novel role for basement membrane PGs in I/R induced renal injury.
Our model, however, was a relatively mild I/R model (25min bilateral occlusion) which
does not lead to extensive post-ischemic fibrosis. For investigating the role of PGs in renal
fibrosis, it would be better to choose a more severely fibrotic model like unilateral ureteric
obstruction in which we can investigate the role of PGs in the fibrotic process regarding
their interaction with innate immune components. Based on the results, a therapeutic
approach with some heparinoids can be considered.
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Furthermore, we were able to show the role of genetic variation in the AP in occurrence
of acute rejection and progressive renal function loss resulting in end stage renal disease in
native kidneys. This is the first time that this association has been shown in a transplant
cohort analysis, and should be replicated in an independent cohort. Additionally, more
mutations in complement factors can be checked in association with renal graft outcome.
The possible role of PGs genetic variants in the renal transplant population would be
interesting to investigate as well. The genetic association studies provides a better insight
to the involvement of complement-PG interaction in the process of renal function loss and
serves as a starting point for further mechanistic studies.
Taken together, it is clear that insight in the molecular interactions in renal diseases is
important to allow the design of novel strategies for treatment. Immune suppressive drugs
used after transplantation mainly target the adaptive immune system, while the activation
of innate immune system in the disease process is mostly neglected. For achieving a better
outcome in treatment of renal diseases including transplantation, considering the role of
innate immune system could provide novel targets for intervention. Our studies in this
thesis provide novel insights in the role of PGs in renal inflammation in relation to innate
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